| Primary |
| Staphylococcal Infection |
50.0% |
| Prophylaxis |
33.3% |
| Preoperative Care |
16.7% |
|
| Feeling Abnormal |
50.0% |
| Hyperpyrexia |
50.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
24.5% |
| Product Used For Unknown Indication |
11.9% |
| Sepsis |
6.1% |
| Pyrexia |
5.8% |
| Pneumonia |
5.5% |
| Hypertension |
4.8% |
| Prophylaxis |
4.6% |
| Infection |
4.2% |
| Staphylococcal Infection |
4.2% |
| Drug Exposure During Pregnancy |
3.8% |
| Fluid Replacement |
3.3% |
| Infection Prophylaxis |
2.9% |
| Sedation |
2.9% |
| Candidiasis |
2.6% |
| Diabetes Mellitus |
2.3% |
| Osteitis |
2.3% |
| Staphylococcal Sepsis |
2.2% |
| Acute Respiratory Distress Syndrome |
2.2% |
| Disseminated Intravascular Coagulation |
2.0% |
| Ureteral Stent Insertion |
1.9% |
|
| Thrombocytopenia |
14.1% |
| Renal Failure Acute |
13.6% |
| Blood Alkaline Phosphatase Increased |
10.0% |
| Pyrexia |
8.0% |
| Renal Failure |
5.3% |
| Toxic Skin Eruption |
4.7% |
| Agranulocytosis |
4.4% |
| Pancytopenia |
4.4% |
| Sepsis |
4.4% |
| Renal Impairment |
4.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.3% |
| Septic Shock |
3.0% |
| Toxic Epidermal Necrolysis |
3.0% |
| Erythema |
2.8% |
| Respiratory Failure |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Neutropenia |
2.5% |
| Vomiting |
2.5% |
| Gamma-glutamyltransferase Increased |
2.2% |
| Clostridium Difficile Colitis |
1.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.2% |
| Drug Use For Unknown Indication |
14.2% |
| Prophylaxis |
8.8% |
| Pneumonia |
6.2% |
| Infection Prophylaxis |
5.1% |
| Adult T-cell Lymphoma/leukaemia |
4.6% |
| Febrile Neutropenia |
3.7% |
| Acute Myeloid Leukaemia |
3.1% |
| Stem Cell Transplant |
2.8% |
| Lung Transplant |
2.7% |
| Sepsis |
2.7% |
| Immunosuppression |
2.7% |
| Acute Myeloid Leukaemia Recurrent |
2.3% |
| Pyrexia |
2.3% |
| Hypertension |
2.2% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Antifungal Prophylaxis |
2.0% |
| Infection |
1.8% |
| Fungal Infection |
1.7% |
| Multiple Myeloma |
1.7% |
|
| White Blood Cell Count Decreased |
13.1% |
| Sepsis |
9.2% |
| Respiratory Failure |
7.1% |
| Platelet Count Decreased |
6.5% |
| Pyrexia |
5.9% |
| Thrombotic Microangiopathy |
5.6% |
| Vomiting |
5.6% |
| Thrombocytopenia |
5.3% |
| Venoocclusive Liver Disease |
5.0% |
| Toxic Epidermal Necrolysis |
4.5% |
| Shock |
4.2% |
| Pneumonia |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Renal Impairment |
3.3% |
| Interstitial Lung Disease |
3.0% |
| Septic Shock |
3.0% |
| Stomatitis |
3.0% |
| Ventricular Tachycardia |
3.0% |
| Weight Increased |
3.0% |
| Death |
2.7% |
|
| Interacting |
| Product Used For Unknown Indication |
29.2% |
| Acute Promyelocytic Leukaemia |
10.8% |
| Depression |
10.8% |
| Hypertension |
9.2% |
| Lung Disorder |
9.2% |
| Thrombophlebitis |
6.2% |
| Atrial Fibrillation |
4.6% |
| Dementia Alzheimer's Type |
4.6% |
| Fungal Infection |
4.6% |
| Oesophagitis |
4.6% |
| Pain |
4.6% |
| Infection |
1.5% |
|
| Drug Interaction |
45.5% |
| International Normalised Ratio Increased |
36.4% |
| Myositis |
18.2% |
|
